SLC5A2 and sarcopenia: The consistent finding of LBM/SMM decline has raised significant concern regarding whether SGLT2 inhibitors can increase the risk of sarcopenia or exacerbate muscle dysfunction, particularly in at-risk groups like the elderly or those with underlying frailty [43].